Neuren Pharmaceuticals' (ASX:NEU) partner, Nasdaq-listed Acadia Pharmaceuticals, submitted a marketing authorization application with the European Medicines Agency for trofinetide, a treatment candidate for Rett syndrome in adults and pediatric patients, according to a Wednesday filing with the Australian bourse.
Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.
The application is expected to be approved in the first quarter of 2026, the filing said.
Additionally, Acadia plans to start managed access programs in Europe in the second quarter of the year, according to the filing.
Neuren Pharmaceuticals shares fell nearly 6% in morning trade Wednesday and earlier hit their lowest since September 2023.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.